BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18-30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial

被引:3
|
作者
Kwiatkowski, Fabrice [1 ]
Dessenne, Pascal [1 ]
Laquet, Claire [1 ]
Daures, Jean-Pierre [2 ,3 ]
Gay-Bellile, Mathilde [1 ]
Bignon, Yves-Jean [1 ]
机构
[1] Ctr Jean Perrin, Lab Oncol Mol, 58 Rue Montalembert, F-63011 Clermont Ferrand, France
[2] Decis Med Personnalisee Montpellier, UPRES 2425, Montpellier, France
[3] Mutualite Clin Beau Soleil, Montpellier, France
关键词
QUALITY-OF-LIFE; HERTH HOPE INDEX; SELF-ESTEEM; PSYCHOMETRIC PROPERTIES; POWERFUL OTHERS; SCORING SYSTEM; VALIDATION; INSTRUMENT; LOCUS; TRANSLATION;
D O I
10.1186/s13063-016-1642-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Young women exposed to a high hereditary breast and ovarian cancer (HBOC) risk are particularly vulnerable. They are ignored by health prevention measures but exposed to a stream of contradictory information (medicine, media, Internet). They may feel concerned about surgical prevention issues at a key moment of their identity construction (self, relationship, sexuality). We designed a special psychoeducational intervention to help these women cope better with these difficulties. Methods/design: The BRACAVENIR study consists of a prospective, randomized superiority phase II trial with a wait list control group. Participants are childless young female counselees (aged 18-30 years) seen at the oncogenetics department of the Centre Jean Perrin and belonging to HBOC families either with or without BRCA mutations. They will be invited to attend a weekend group session at a spa resort and to participate in short expert conferences and focus group activities (group sharing, Moreno role game) supervised by a psychotherapist. Two sessions separated by a 6-month delay (wait list) will enable us to evaluate the intervention's effect by comparing questionnaire scores between the 6-month time points. The main endpoint is an increase of the Herth Hope Index by at least 1 SD. Secondary endpoints are self-esteem, anxiety trait, anxiety state, coping, and quality of life. With a one-sided alpha = 0.05 and beta = 0.20, 12 participants will be needed by group, plus an additional 2 in anticipation of dropouts. Participants will be randomized 1:1 to the first or the second session so that the groups will be comparable. Discussion: The intent of this trial is to bridge the gap on a psychosocial level in these young women with HBOC. A particularity of the design is the use of a waiting list, which should allow for avoiding major bias. The intervention consists of a short session that could be proposed to other young counselees if successful. The results may bring complementary information to facilitate the intervention and also influence the contents of the oncogenetic consultation.
引用
收藏
页数:10
相关论文
共 14 条
  • [1] BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18–30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial
    Fabrice Kwiatkowski
    Pascal Dessenne
    Claire Laquet
    Jean-Pierre Daures
    Mathilde Gay-Bellile
    Yves-Jean Bignon
    [J]. Trials, 17
  • [2] BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer
    Fabrice Kwiatkowski
    Mathilde Gay-Bellile
    Pascal Dessenne
    Claire Laquet
    Véronique Boussion
    Marie Béguinot
    Marie-Françoise Petit
    Anne-Sophie Grémeau
    Céline Verlet
    Charlotte Chaptal
    Marilyn Broult
    Sylvie Jouvency
    Martine Duclos
    Yves-Jean Bignon
    [J]. Hereditary Cancer in Clinical Practice, 17
  • [3] BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer
    Kwiatkowski, Fabrice
    Gay-Bellile, Mathilde
    Dessenne, Pascal
    Laquet, Claire
    Boussion, Veronique
    Beguinot, Marie
    Petit, Marie-Francoise
    Gremeau, Anne-Sophie
    Verlet, Celine
    Chaptal, Charlotte
    Broult, Marilyn
    Jouvency, Sylvie
    Duclos, Martine
    Bignon, Yves-Jean
    [J]. HEREDITARY CANCER IN CLINICAL PRACTICE, 2019, 17 (1)
  • [4] Couplelinks - an online intervention for young women with breast cancer and their male partners: study protocol for a randomized controlled trial
    Fergus, Karen
    Ahmad, Saunia
    McLeod, Deborah L.
    Stephen, Joanne
    Gardner, Sandra
    Pereira, Amanda
    Warner, Ellen
    Carter, Wendy
    [J]. TRIALS, 2015, 16
  • [5] Couplelinks - an online intervention for young women with breast cancer and their male partners: study protocol for a randomized controlled trial
    Karen Fergus
    Saunia Ahmad
    Deborah L McLeod
    Joanne Stephen
    Sandra Gardner
    Amanda Pereira
    Ellen Warner
    Wendy Carter
    [J]. Trials, 16
  • [6] Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention
    Crew, Katherine D.
    Silverman, Thomas B.
    Vanegas, Alejandro
    Trivedi, Meghna S.
    Dimond, Jill
    Mata, Jennie
    Sin, Margaret
    Jones, Tarsha
    Terry, Mary Beth
    Tsai, Wei-Yann
    Kukafka, Rita
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 16
  • [7] The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress
    Kim, Hyun-Ah
    Ahn, Sei Hyun
    Nam, Seok Jin
    Park, Seho
    Ro, Jungsil
    Im, Seock-Ah
    Jung, Yong Sik
    Yoon, Jung Han
    Hur, Min Hee
    Choi, Yoon Ji
    Lee, Soo-Jung
    Jeong, Joon
    Cho, Se-Heon
    Kim, Sung Yong
    Lee, Min Hyuk
    Kim, Lee Su
    Moon, Byung-In
    Kim, Tae Hyun
    Park, Chanheun
    Kim, Sei Joong
    Jung, Sung Hoo
    Park, Heungkyu
    Gwak, Geum Hee
    Kang, Sun Hee
    Kim, Jong Gin
    Kim, Jeryong
    Choi, Su Yun
    Lim, Cheol-Wan
    Kim, Doyil
    Yoo, Youngbum
    Song, Young-Jin
    Kang, Yoon-Jung
    Jung, Sang Seol
    Shin, Hyuk Jai
    Lee, Kwan Ju
    Han, Se-Hwan
    Lee, Eun Sook
    Han, Wonshik
    Kim, Hee-Jung
    Noh, Woo Chul
    [J]. BMC CANCER, 2016, 16
  • [8] The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress
    Hyun-Ah Kim
    Sei Hyun Ahn
    Seok Jin Nam
    Seho Park
    Jungsil Ro
    Seock-Ah Im
    Yong Sik Jung
    Jung Han Yoon
    Min Hee Hur
    Yoon Ji Choi
    Soo-Jung Lee
    Joon Jeong
    Se-Heon Cho
    Sung Yong Kim
    Min Hyuk Lee
    Lee Su Kim
    Byung-In Moon
    Tae Hyun Kim
    Chanheun Park
    Sei Joong Kim
    Sung Hoo Jung
    Heungkyu Park
    Geum Hee Gwak
    Sun Hee Kang
    Jong Gin Kim
    Jeryong Kim
    Su Yun Choi
    Cheol-Wan Lim
    Doyil Kim
    Youngbum Yoo
    Young-Jin Song
    Yoon-Jung Kang
    Sang Seol Jung
    Hyuk Jai Shin
    Kwan Ju Lee
    Se-Hwan Han
    Eun Sook Lee
    Wonshik Han
    Hee-Jung Kim
    Woo Chul Noh
    [J]. BMC Cancer, 16
  • [9] New Moms Wellness Study: the randomized controlled trial study protocol for an intervention study to increase fruit and vegetable intake and lower breast cancer risk through weekly counseling and supplemental fruit and vegetable box delivery in breastfeeding women
    Sturgeon, Susan R.
    Sibeko, Lindiwe
    Balasubramanian, Raji
    Arcaro, Kathleen F.
    [J]. BMC WOMENS HEALTH, 2022, 22 (01)
  • [10] New Moms Wellness Study: the randomized controlled trial study protocol for an intervention study to increase fruit and vegetable intake and lower breast cancer risk through weekly counseling and supplemental fruit and vegetable box delivery in breastfeeding women
    Susan R. Sturgeon
    Lindiwe Sibeko
    Raji Balasubramanian
    Kathleen F. Arcaro
    [J]. BMC Women's Health, 22